Bdaxit contains axitinib, a targeted cancer therapy known as a tyrosine kinase inhibitor. It is used primarily in the management of advanced kidney cancer, offering patients a treatment option that slows tumor progression by interfering with the growth of new blood vessels that feed the cancer. As an oral therapy, Bdaxit offers convenience and flexibility for long-term treatment.

Mechanism of Action
Axitinib works by selectively inhibiting vascular endothelial growth factor receptors known as VEGFR 1, 2, and 3. These receptors play a key role in angiogenesis, the process by which new blood vessels form. Tumors rely on this process to receive nutrients and oxygen for continued growth. By blocking VEGFRs, axitinib reduces blood flow to the tumor, effectively starving cancer cells and slowing their growth and spread.

Uses
Bdaxit is mainly prescribed for the treatment of advanced renal cell carcinoma, especially in patients who have not responded well to previous treatments. It is often used as a second-line therapy following failure of other drugs such as sunitinib or cytokine-based treatments. The goal of therapy is to delay disease progression and improve survival while maintaining quality of life.

Adverse Effects
Common side effects include high blood pressure, diarrhea, fatigue, loss of appetite, and weight loss. Some patients may also experience hand-foot syndrome, hoarseness, or changes in thyroid function. More serious but less common risks include bleeding, blood clots, liver enzyme abnormalities, and gastrointestinal perforation. Regular blood pressure monitoring and laboratory tests are important during treatment to manage any emerging side effects early.